Moderna Inc (MRNA) Stock: Uncovering a 52-Week Range and Trading Volume

A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Moderna Inc’s current trading price is -44.94% away from its 52-week high, while its distance from the 52-week low is 56.13%. The stock’s price range for this time frame has been between $62.55 and $177.37. The trading volume of the company’s shares in the Healthcare reached around 0.92 million for the day, which was evidently lower than the average daily volume of 4.64 million over the last three months.

Moderna Inc’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $177.37 on 02/15/23, and the lowest price during the same period was recorded at $62.55 on 11/02/23.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

How Financial Performance Impacts Market Capitalization

Moderna Inc (MRNA) has experienced a quarterly rise of 32.58% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 37.24B and boasts a workforce of 3900 employees.

The Role of Moving Averages and Trading Volume in Technical Analysis

Based on Barchart.com data, the company’s moving average over the 100-day period was 91.08, with a change in price of -16.55. Similarly, Moderna Inc recorded 4,520,990 in trading volume during the last 100 days, posting a change of -14.45%.

How MRNA’s Debt-to-Equity Ratio Affects Financial Health

A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for MRNA stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.09.

MRNA Stock Stochastic Average

The raw stochastic average for Moderna Inc over the last 50 days is presently at 58.02%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 23.24%. Further, the company’s Stochastic %K and %D values for the last 20 days were 27.75% and 21.68%, respectively.

MRNA Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price decrease of -1.80%. However, over the past six months, we’ve seen a stronger performance of -4.08%. The price of MRNA leaped by -11.36% over the last 30 days. And in the last five days, it has fallen by -1.37%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts